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See Article, pages 1114–1122 & 1130 –1136HCV infects an estimated 170 million people and is the leading
indication for liver transplantation. For patients harboring infec-
tion with HCV-1, the predominant genotype worldwide, treat-
ment with peginterferon and ribavirin produces sustained
virologic response (SVR) in only 45% of patients and is limited
by substantial side effects [1]. In the coming months, HCV ther-
apy will enter a new era with the introduction of direct acting
antiviral agents (DAAs) [2–5].
The most advanced HCV DAAs in the development pipeline
include inhibitors of the viral NS3/4A protease and the viral
NS5B RNA-dependent RNA polymerase [2]. Inhibitors of the
NS3/4A protease are particularly attractive, since these drugs
may have the double-edged action of not only directly inhibit-
ing HCV replication, but also abrogating HCV NS3/4A’s subver-
sion of the innate immune response [6]. The NS3/4A
compounds currently furthest along in development, the linear
protease inhibitors (PIs) boceprevir (Merck) and telaprevir (VX
950, Vertex), have shown that they can substantially improve
SVR when used in combination with peginterferon and ribavi-
rin, and may also permit truncation of therapy [7–9]. Phase 3
trials of these PIs have been recently completed [2], and their
results are anxiously awaited by patients and HCV providers
alike. The arrival of these drugs heralds a major advance for
HCV therapy, though they are associated with important limi-
tations. Both agents require thrice daily dosing; telaprevir has
also been associated with skin reactions, and boceprevir with
anemia and dysgeusia. As DAAs, both drugs are associated with
rapid development of resistance mutations when given as
monotherapy [7–9] (Table 1).
Two phase 1b studies of new NS3/4A protease inhibitors pub-
lished in this issue of the Journal of Hepatology [10,11] provide
promising evidence that HCV treatment options will continue
to improve. Forestier et al. present phase 1b study results for
the NS3/4A protease inhibitor danoprevir (ITMN 191/RG7227).
Danoprevir is a macrocyclic PI notable for its high speciﬁcity
[12,13] and high hepatic concentrations [13]. Their study evalu-
ated safety, pharmacokinetics, and antiviral activity of 14 days
of danoprevir monotherapy administered two or three times
daily in multiple ascending doses versus placebo in two groups:
40 treatment naïve genotype 1 infected patients (TNs) and 10Journal of Hepatology 20
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E-mail address: rtchung@partners.org (R.T. Chung).peginterferon and ribavirin non-responders (NRs). Subjects were
predominantly male, non-obese, and non-cirrhotic. Danoprevir
monotherapy was safe and well tolerated in both groups, with
limited side effects. HCV RNA declines occurred in all treatment
groups and were dose dependent, with median maximal declines
ranging from 1.8 to 3.9 logs. Viral kinetics revealed that, overall,
27% of patients experienced viral rebound, 35% plateau, and
38% continuous viral decline, including 3/8 prior non-responders,
although the nonresponse category (e.g., null versus partial ver-
sus relapser) was not speciﬁed.
As anticipated, resistance mutations were detected. All
patients with virologic rebound, including GT1b patients, selected
R155K mutations; another two also had D168V/E/T mutations.
Half of the patients who experienced virologic plateau selected
for R155K or D168V/E/T mutations. Not surprisingly, GT1a
patients exhibited rebound more often and selected for a higher
frequency of R155K mutations, likely since 1a virus requires only
one nucleotide substitution to generate this mutant, whereas 1b
requires two substitutions [14]. Of note, R155K mutants, which
may confer cross class resistance [15], persisted following treat-
ment cessation. This ﬁnding is consistent with the report that
these mutants may display ﬁtness resembling that of wild type
HCV [15]. Conversely, D168 mutations may lead to macrocyclic
PI resistance but may actually increase susceptibility to linear
PIs [15]. These patterns will need to be conﬁrmed with longer
term follow-up. Finally, Forestier et al. observed an inferior viro-
logic response in NRs versus TNs, despite equal to higher drug
exposure in NRs. This phenomenon suggests an important role
for the innate immune response, which is likely to be impaired
in most peginterferon and ribavirin non-responders, and may still
be critical even in the setting of monotherapy with DAAs. NS3/4A
inhibitors may unmask an innate immune response ordinarily
suppressed by the NS3/4A protein [6]. This liberated immune
response may vary signiﬁcantly from patient to patient, and
may or may not correlate with the IL28B genotype [16].
While it will be important to track the results of ongoing
phase 2b studies of new generation PIs combined with stan-
dards of care, the greatest focus will and should be placed
on efforts to combine these agents with other DAA classes, par-
ticularly nucleoside HCV NS5b polymerase inhibitors, a DAA
class that offers an exceptionally high barrier to resistance
[17,18].
Also in this issue, Manns et al. present a phase 1b multiple
ascending dose study of a second generation NS3/4A inhibitor,11 vol. 54 j 1087–1089
Table 1. Comparison of 1st and 2nd generation HCV NS3/4A protease inhibitors.
Generation 
1 st 
  Telaprevir 
  Boceprevir 
2 nd
   Danoprevir 
  BI201335 
Structure 
Linear 
Linear 
Macrocyclic 
Macrocyclic 
Genotype 
Coverage 
1a/b 
1a/b 
1a/b, 
1a/b 
Potency 
High 
High 
High 
High 
Potency Data 
w/ Peg-RIBA 
Clinical Data 
Clinical Data 
Preclinical Data 
Clinical Data  
Toxicity 
Rash, 
anemia 
anemia 
Dysgeusia, 
Headache 
Rash, 
Bilirubin 
Dosing 
Tid 
Tid 
Bid-tid 
Daily 
Barrier to 
Resistance 
Low 
Low 
Low 
Low 
Resistance 
Patterns 
V36M/A 
T54A/S 
V55A 
R155K/T 
A156S/V/T 
V170A 
*both 
telaprevir and 
boceprevir%
R155K/Q 
D168V/E/T 
*both 
danoprevir
and BI201335 
?4,5,6** 
⁄⁄Seiwert et al. Antimicrobial Agents and Chemotherapeutics 2008. % Susser et al. Hepatology 2009.
?4,5,6 indicates that there may be danoprevir activity vs HCV genotypes 4,5,6 based on preclinical data but no clinical trials have examined this yet.
EditorialBI201335, in 34 treatment naïve patients and 19 treatment expe-
rienced patients with genotype 1 HCV [11]. Patients were middle
aged, non-obese Caucasians and Asians. One major advantage of
BI201335 is its once daily dosing schedule. In contrast to the
study of Forestier, which was conﬁned to study of monotherapy,
Manns et al. evaluated monotherapy followed by combination
therapy (BI201335/pegylated interferon/ribavirin) in treatment
of naïve patients with >=1 log HCV decline after 14 days of
DAA. Treatment experienced patients only received combined
therapy, with no monotherapy phase. Ninety-six percent of
patients receiving BI120335 monotherapy achieved a >=2 log
HCV RNA decline at some point, though, as with danoprevir,
monotherapy was associated with the frequent selection of resis-
tance mutations, including R155K and D168V/E. In contrast to
danoprevir, however, B1201335 resistance mutations stratiﬁed
almost completely by HCV subtype (1a developed R155, 1b devel-
oped D168V/E), again consistent with a lower barrier to selection
of R155K in 1a infection [14]. Side effects were mild, although a
rash was reported in 4/34 patients on DAA with SOC, and the
authors cite a slightly increased frequency of rash in ongoing
phase II trials. In addition, indirect hyperbilirubinemia was
detected in patients on high dose mono- and combination ther-
apy; the mechanism underlying this phenomenon is currently
under investigation [11].
Overall, these two DAA studies represent an important step
forward toward the eradication of HCV [19]. Their major contri-
butions include potent antiviral effects with a lower pill burden
and manageable side effect proﬁles. The major drawback of these
drugs, as expected, is selection of resistant variants during mono-
therapy. While monotherapy studies are important for the evalu-
ation of safety, it is clear that monotherapy is not a viable long
term strategy, and that DAAs will for now need to be added onto
a backbone of peginterferon and ribavirin. For the particular case1088 Journal of Hepatology 2011of prior null responders, added caution will be required, since
retreatment with a single DAA added to SOC may amount to
the functional equivalent of DAA monotherapy. Indeed, phase 2
and 3 data in null responder populations have shown high rates
of residual viremia enriched for NS3/4A mutations. The success
rates of about 30% SVR for prior null responders treated with
PEG/RBV and telaprevir suggests that only those null responders
with more advanced histologic disease should be offered the
combination of PEG/RBV/PI therapy [20]. For prior null respond-
ers, referral to a clinical trial including at least two DAA agents
with PEG and RBV may need to be considered. While sequencing
studies have suggested the gradual regression of most PI-resis-
tant variants to wildtype virus over time [14], the long term
implications of these ﬁndings is unclear. For instance, it is
unknown how quickly PI-resistant virus will be selected with
re-exposure to PI-containing regimens. The clonal sequencing of
viral populations using sensitive measures such as ultradeep
pyrosequencing will help to clarify the correlates of rapid re-
selection of resistance. The additional ﬁnding that some PI-resis-
tant variants may retain ﬁtness comparable to wildtype virus
[15] bolsters the argument that monotherapy, even for a short
time, could limit future treatment options for patients enrolled
in clinical trials.
In summary, the two studies that have been described provide
further welcome news that HCV protease inhibitors with
improved side effect proﬁles and decreased dose frequency are
on the horizon, just behind the ﬁrst generation of PIs. We can
anticipate that these agents will eventually supplant ﬁrst gener-
ation PIs not only in combination with PEG and RBV, but, more
importantly, as cardinal components of future IFN-sparing DAA
cocktails. These considerations place a premium on both adher-
ence and tolerability. In 2011 and beyond, HCV providers must
now rise to the challenge of quickly assimilating and carefullyvol. 54 j 1087–1089
JOURNAL OF HEPATOLOGY
applying DAA data as it unfolds. Great care will be necessary to
counsel against unnecessary therapy in persons who have a low
likelihood of responding to PEG/RBV and a PI, including those
persons with prior null response to PEG/RBV, and limited hepatic
ﬁbrosis. We will therefore likely require a substantial re-educa-
tion campaign for providers in the coming years. The future
appears bright, provided we proceed with an appropriate mea-
sure of circumspection.Disclosure
The authors declared a relationship with the manufacturers of
the drugs involved. Tibotec-Advisory Board 2009. Roche-Clinical
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